Recent Updates
Recently added Catalysts

RTN-001

Phase 2

Uncontrolled Hypertension | Small molecule | Cardiovascular |Retension Pharmaceuticals, Inc.|Trials Updated: Oct 2, 2026

RTN-001 development status

Highest phase Phase 2
Registered trials 3 across 1 sponsor since Nov 2007

RTN-001 target and mechanism

ModalitySmall molecule

Also known as SLx-2101

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials3
Total Enrollment344

FDA Designations

No designations recorded

RTN-001 clinical trials

RTN-001 · 3 trials · 2 indications

Phase 2 3
NCT07142356A Study of Modified Release RTN-001 In Patients With Uncontrolled HypertensionUncontrolled Hypertension
RECRUITING280 Analytics
NCT00562549Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With HypertensionHypertension
COMPLETED26 Analytics
NCT00562614Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With HypertensionHypertension
COMPLETED38 Analytics
PHASE2RECRUITING
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Uncontrolled Hypertension
NCT07142356280
Unlock trial analytics
PHASE2COMPLETED
Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension
Hypertension
NCT0056254926
Unlock trial analytics
PHASE2COMPLETED
Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension
Hypertension
NCT0056261438
Unlock trial analytics

Study Endpoints

Primary Endpoints

Mean change in systolic blood pressure (SBP) at 4 weeks
4 weeks

The difference in the mean change in pre-dose office-seated peripheral systolic blood pressure in patients with uncontrolled hypertension after 4 weeks of treatment with RTN-001 versus placebo.

Office seated peripheral systolic and diastolic blood pressure
12 days
Peripheral systolic, diastolic blood pressures and heart rates
14 days

Secondary Endpoints

Mean change in pre-dose office-seated SBP at 2, 8, and 12 weeks
2, 8, and 12 weeks
Mean change in pre-dose central SBP at 2, 4, 8, and 12 weeks
2, 4, 8, and 12 weeks
Mean change in daytime ambulatory SBP at 4 and 12 weeks
4 and 12 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
RTN-001 (15 mg)EXPERIMENTAL -
RTN-001 (30 mg)EXPERIMENTAL -
RTN-001 (45 mg)EXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
1EXPERIMENTALSLx-2101
2PLACEBO_COMPARATORMatching Placebo Dose

Interventions

NameTypeDescription
RTN-001DRUGOral tablet
Matching placebo controlDRUGOral tablet with similar appearance as the RTN-001.
SLx-2101DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites34

Inclusion Criteria: * Male or female patients age 18 to 75 years, inclusive, at the Screening Visit. * Uncontrolled HTN despite being on a stable regimen of 2-5 antihypertensive medications. * Mean BP of ≥135/80 mm Hg. * Body mass index of 18 to 35 kg/m2. Exclusion Criteria: * Mean seated SBP \>1...

Countries:United StatesUnited KingdomGermany
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Retension Pharmaceuticals, Inc. (RTSN)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with RCompanies A to ZEvery biotech and pharma company we track